Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022787 | 0.81 | BRD4 (0.32) | GRIN2B | |
| SCHEMBL20022785 | 0.81 | CHRNB2 (0.34) | SMOLTA4HGRIN2BGRIN1MEN1 | |
| SCHEMBL20022782 | 0.80 | ALDH1A1 (0.37) | SMOLTA4HFAAHGRIN2BGRIN1 | |
| SCHEMBL20022792 | 0.78 | RAB9A (0.36) | MEN1KMT2A | |
| SCHEMBL20022803 | 0.78 | BRD4 (0.31) | GRIN2B | |
| SCHEMBL20022781 | 0.71 | SMN1; SMN2 (0.42) | SMOFAAHKMT2A | |
| SCHEMBL20028531 | 0.67 | LTA4H (0.34) | SMOLTA4HMEN1KMT2A | |
| SCHEMBL18209875 | 0.63 | LTA4H (0.32) | LTA4H | |
| SCHEMBL20028324 | 0.62 | SMO (0.37) | SMOLTA4HFAAHKMT2A | |
| SCHEMBL20022786 | 0.62 | GRIN2B (0.33) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | SMO 3294/4885LTA4H 58/4885FAAH 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.